Market Overview

Genpact Awarded Five-Year Contract Extension by GlaxoSmithKline

Related G
Coverage Initiated on Accenture - Analyst Blog
Timon And Pumba Find GrubHub In The Dirt As IPO Stumbles

Genpact (NYSE: G), a global leader in business process management and technology services, today announced it has been awarded a five-year contract extension by global pharmaceutical leader GlaxoSmithKline (NYSE: GSK) for finance and accounting (F&A) services.  Under this agreement, Genpact will continue to deliver global services such as accounts payable, record-to-report, and order-to-cash across several global regions, supporting GSK's drive to standardize core business processes and services.

(Logo: http://photos.prnewswire.com/prnh/20120501/NY98560LOGO )

Paul Fry, senior vice president for Finance Services in GSK's Core Business Services said, "Our continued partnership with Genpact is a key element in our drive to deliver simpler, more efficient and standardized business processes for GSK."

"Over the last six years, the partnership between Genpact and GSK has been able to address GSK's growing global business and the unique challenges within the pharmaceutical market while improving the outcomes of these end-to-end processes, especially through our Lean and Six Sigma framework," said BK Kalra, senior vice president and business leader, Life Sciences, Genpact.   "We are thrilled to expand our valued relationship with GSK and ensure continuous process effectiveness so that their path to future growth is smooth."

Genpact provides business process management and technology services to

See full press release

Posted-In: News Guidance Contracts Management Global

 

Most Popular

Related Articles (G + GSK)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free